Targeting a new nanoantibody for ADAMTS5 osteoarthritis, Merck awarded it to Novartis for 50 million euros.

Merck KGaA has signed a licensing agreement with Novartis to develop clinical studies of osteoarthritis drugs.
protocol covers the phase II clinical anti-ADAMTS5n antibody M6495, a drug developed for patients to inject themselves under the skin to maintain the structural integrity of the knee joint and reduce pain.
has completed two Phase I studies of M6495: one in healthy volunteers showing safety and tolerance, and the other observing a significant decrease in ANGS, a new cousin found in the fluid and serum of osteoarthritis patients.
photo source: 2019 ACR/ARP Annual Meeting Osteoarthritis is a chronic progressive disease characterized by the degression of joint cartilage.
metal protease ADAMTS5 is the main cause of cartilage degradation in arthritis disease.
: Under the terms of the deal, Merck will license the M6495 to Novartis for further evaluation of osteoarthritis patients.
, Merck will receive an advance of 50 million euros and possibly another 400 million euros related to business milestones and sales royalties.
.